DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03856632

LEAF

Active not recruitingPhase 4

Liraglutide Effect in Atrial Fibrillation

Novel Medical Adjunctive Therapy to Catheter Ablation For Atrial Fibrillation (AF)

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

60

actual

Study population

Atrial fibrillation, Obesity / overweight

Key I/E criterion

•BMI ≥27

Primary endpoint

•Size of Left Atrial Epicardial Adipose Tissue (LAEAT)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03856632
Org study ID20181182

Timeline

Milestones

Study first posted2019-02-27actual
Study start2019-03-18actual
Last update posted2026-05-01actual
Primary completion2026-12-31estimated
Study completion2026-12-31estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Atrial fibrillationObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Male and female, age 18 or older
•Persistent AF defined as continuous AF sustained beyond 7 days (or AF with the decision to cardiovert before 7 days of enrollment or Paroxysmal AF defined as recurrent AF (≥2 episodes) that terminates spontaneously within 7 days
•BMI ≥27 kg/m2
•Patient wishes to undergo a catheter ablation procedure for the treatment of atrial fibrillation
•Receiving follow-up care at the University of Miami

Exclusion criteria

•Inability to sign an informed consent
•Patients with longstanding persistent atrial fibrillation of more than 3 years
•Prior ablation for atrial fibrillation
•Patients not appropriate candidates for catheter ablation such as those with AF due to acute or chronic precipitating medical conditions, for example, hypothyroidism and hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial thrombus, class IV heart failure)
•Patients with a life expectancy <1 year
•Patients with a serious medical condition (for example, recent cancer with chemotherapy or radiation therapy within 4 weeks before entering the study) who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
•Known contraindications to Liraglutide, such as the previous history of pancreatitis or medullary thyroid carcinoma
•Personal or family history of multiple endocrine neoplasias
•Known serious hypersensitivity reaction to Liraglutide
•Patients using, glitazones, sodium-glucose transporters 2 inhibitors (SGLT2i), other GLP-1 analogs, or DPP4 inhibitors
•Type 1 diabetes, defined by American Diabetes Association criteria, history of diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to pancreatitis or pancreatectomy
•Poorly controlled type 2 diabetes with HbA1c > 10%
•Pregnant women
•Women who are breast-feeding or intend to become pregnant

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
5
Weight & body composition
2
Cardiometabolic biomarkers
2
Heart failure
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

Change in size of Left Atrial Epicardial Adipose Tissue (LAEAT)

Time frame:Baseline, 3 months (prior to ablation)

change from baseline, improvement

Secondary/protocol endpoint

Change in size of Epicardial Adipose Tissue (EAT) thickness

Time frame:Baseline, 3 months (prior to ablation), 1 year post-ablation

change from baseline, improvement

Heart failure

1 endpoint
Secondary/protocol endpoint

Correlation of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)

Time frame:During the catheter ablation procedure

descriptive

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Change in C-Reactive Protein (CRP) value

Time frame:Baseline, 1 year post ablation

change from baseline, improvement

Secondary/protocol endpoint

Correlation of CRP expression in blood from left atrium to peripheral plasma

Time frame:During the catheter ablation procedure

hs-CRP, change

descriptive

LOINC 30522-7

Other (unclassified)

5 endpoints
Secondary/protocol endpoint/low confidence

Change in atrial function

Time frame:Baseline, 1 year post ablation

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in atrial size

Time frame:Baseline, 1 year post ablation

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in Interleukin-6 (IL-6)

Time frame:Baseline, 1 year post ablation

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Correlation of IL-6 expression in blood from left atrium to peripheral plasma

Time frame:During the catheter ablation procedure

descriptive

Secondary/protocol endpoint/low confidence

Correlation of plasminogen activator inhibitor (PAI-1), matrix metalloproteinase-2 (MMP2), Tissue inhibitor of metalloproteinase 2 (TIMP-2)

Time frame:During the catheter ablation procedure

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.